Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Research News
 
In-Vitro Innervation: Stem Cell-Derived Motor Neurons Meet Muscles
16 May 2012. Scientists have made strides turning stem cells into motor neurons, but a motor neuron is useful only when it innervates a muscle...
 
Q&A With Genentech Lead Scientist on API Trial Ryan Watts
16 May 2012. Ryan Watts of Genentech is the founding research scientist on the clinical trial collaboration with the Alzheimer’s Prevention Initiative...
 
NIH Director Announces $100M Prevention Trial of Genentech Antibody
16 May 2012. Francis Collins announced that $16 million of federal funds would go toward the first-ever therapeutic prevention trial in cognitively healthy people...
 
DIAN: What Sayeth the Regulator? Q&A With Rusty Katz
15 May 2012. When the DIAN convened its Pharma Consortium, its scientists intended to brief the Food and Drug Administration on how far DIAN’s work has advanced to date...
 
GO TO ALL RESEARCH NEWS  
 
 
In the spotlight
Prevention Trial in Familial AD Will Test Genentech Antibody
The first asymptomatic treatment trial of an investigational Alzheimer's immunotherapy got the go-ahead when a three-way collaboration among the biotech company Genentech, the federal government, and private philanthropy
was forged to fund it and to provide both drug and expertise.

The five-year trial will test the antibody crenezumab in Colombian carriers of the Paisa mutation in presenilin-1, and in some U.S. carriers of other presenilin and APP mutations. At the Alzheimer's Disease Research Summit 2012 in Washington, D.C., NIH Director Francis Collins announced that the trial, as well as a second trial of intranasal insulin in MCI, were part of the National Plan to Address Alzheimer’s Disease, which HHS Secretary Kathleen Sebelius released on 15 May 2012.
NIH Director Announces $100M Prevention Trial of Genentech Antibody
Q&A With Genentech Lead Scientist on API Trial Ryan Watts

DIAN Progress Update
At the Alzheimer's Disease Research Summit 2012, being held 14-15 May at the National Institutes of Health, speakers cited the Dominantly Inherited Alzheimer Network (DIAN) as an example of the kind of integrated observational and treatment initiative that advances the field. Click for highlights from DIAN's most recent trial preparation meeting on 15 April 2012.

DIAN Grows, Gets Ready for Therapeutic Trials
What Sayeth the Regulator? Q&A With Rusty Katz
Read a PDF of the series.
Robots Take Over Patch-Clamp
View larger image
For decades, neuroscientists have struggled to learn the precise strategy necessary to perform patch-clamp electrophysiology on neurons in a living brain. Like so many once uniquely human endeavors, this is something that robots now do as well as or better than people.

As reported in the May 6 Nature Methods online, researchers at MIT and the Georgia Institute of Technology in Atlanta developed a robot to slide a pipette through tissue, checking for cells near its tip along the way until it finds one to patch and analyze. At 90 percent accuracy in detecting cells, and managing a recording in one-third of its tries, it bests many human hands. Read the full story. Image credit: Sputnik Animation and MIT McGovern Institute
Keystone: Researchers Report on Traumatic Encephalopathy Meeting
Traumatic brain injury is now widely recognized as a major public health concern. Whether on the battlefield or the playing field, blows to the head can lead to encephalopathies that mimic aspects of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The recent suicide of retired NFL star Junior Seau of a gunshot to
the chest has many wondering if he, too, suffered from chronic brain damage. According to media reports, Seau’s brain will be examined.

Similar cases were on scientists’ minds when they gathered at Keystone, Colorado, 26 February-2 March 2012 to discuss advances in the study of acute and chronic traumatic encephalopathies. Meeting co-organizer Samuel Gandy enlisted the help of colleagues Soong Ho Kim and Effie Mitsis to prepare summaries of the symposium, and many of the speakers graciously made their slide decks available for the field at large to see.
Traumatic Brain Injury—Epidemiology and Characteristics
Sports-Related Injury and Chronic Traumatic Encephalopathy
Metabolic and Axonal Dysfunction in Traumatic Brain Injury
TBI—Learning From Markers, Models, and Diseases
Diagnosis and Model Treatments for Traumatic Brain Injury
Read a PDF of the entire series.

 
 
What's New
Comments - Posted 16 May 2012
Read remarks by Vincent Villette about Verret L et al.
PAPER: Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model.
 
Comments - Posted 16 May 2012
Read remarks by Jeffrey L. Noebels about Verret L et al.
PAPER: Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model.
 
Comments - Posted 15 May 2012
Read remarks by Sanjay W. Pimplikar about Desikan RS et al.
NEWS: Biomarker Duo Signals Mental Decline
 
Comments - Posted 15 May 2012
Read remarks by Jurgen Goetz about Batish M et al.
PAPER: Neuronal mRNAs travel singly into dendrites.
 
Comments - Posted 15 May 2012
Read remarks by Amany Mohamed, Elena Posse de Chaves about Mohamed A et al.
NEWS: Aβ42 Oligomers Block Cholesterol Synthesis, Protein Prenylation
 
Comments - Posted 15 May 2012
Read remarks by John Cirrito about Kodandaramaiah SB et al.
NEWS: Research Brief: Robots Trained in Patch-Clamp Experiments
 
Comments - Posted 15 May 2012
Read remarks by Chris Exley about Laganowsky A et al.
NEWS: Anti-parallel Universe—Rare Amyloid Peptides in Cylinders, Sheets
 
Comments - Posted 15 May 2012
Read remarks by Eduardo Cumbo about Bakker A et al.
PAPER: Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.

SEE MORE  
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Most E-mailed Most Commented
Forum Calendar

Check out our most recent Webinar: “Network Epicenters” in Healthy Connectome Predict Dementia.

Listen to the recording of Claudia Kawas' HAI keynote lecture at our ongoing Forum Webinar: AD in the Oldest Old—What Does Aβ Have to Do With It?

AlzGene
PDGene
SZGene
MSGene
ALSGene
An up-to-date collection of all published genetic association studies.
Coalition Against Major Diseases (CAMD)
Visit C-Path's Coalition Against Major Diseases to learn about its collaborative efforts in Alzheimer's and Parkinson's.
C-Path
AlzRisk: An AD Epidemiology Database
The AlzRisk Epidemiology Database provides a publicly available collection of published studies on the impact of putative environmental risk factors and protective factors related to Alzheimer disease in longitudinal cohort studies.
Topics in Neurodegeneration
Download Powerpoint Presentations created by top experts in neurodegenerative disease research. Available for educational or personal use. Edited by Daniel M. Michaelson, PhD, and Tobias Hartmann, PhD.

Copyright © 1996-2012 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad